secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0001701541-25-000014
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics reports Q4/FY2024 net loss $16M/$69.7M; cash $98.6M into Q4 2026
--------------------------------------------------------------------------------

- Cash, cash equivalents, and investments $98.6M at Dec 31, 2024, down from $131.4M at Dec 31, 2023.
- Net loss for Q4 2024 was $16.0M, compared to $19.4M in Q4 2023; FY2024 net loss $69.7M vs $82.4M.
- R&D expenses decreased to $12.3M in Q4 2024 from $15.3M in Q4 2023; FY2024 R&D $51.3M vs $59.4M.
- Initial Phase 2 data for BDTX-1535 in newly diagnosed non-classical EGFRm NSCLC expected Q2 2025.
- Cash runway expected into Q4 2026; management to seek FDA feedback on registrational path for BDTX-1535 in H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000170154125000014/0001701541-25-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000170154125000014/bdtx-20250306.htm
  HTML page:      https://secwatch.observer/filing/0001701541-25-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer